John Mcgrath Sells 14,000 Shares of Atara Biotherapeutics Inc (ATRA) Stock

Atara Biotherapeutics Inc (NASDAQ:ATRA) CFO John Mcgrath sold 14,000 shares of the firm’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $20.65, for a total value of $289,100.00. Following the transaction, the chief financial officer now owns 119,327 shares of the company’s stock, valued at approximately $2,464,102.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

John Mcgrath also recently made the following trade(s):

  • On Friday, March 10th, John Mcgrath sold 24,000 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $20.00, for a total value of $480,000.00.
  • On Tuesday, February 21st, John Mcgrath sold 9,000 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $15.14, for a total value of $136,260.00.

Atara Biotherapeutics Inc (NASDAQ:ATRA) opened at 20.40 on Tuesday. The stock’s market cap is $593.42 million. Atara Biotherapeutics Inc has a 52-week low of $12.45 and a 52-week high of $25.73. The company has a 50-day moving average price of $17.53 and a 200 day moving average price of $17.10.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, March 9th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.35. On average, analysts expect that Atara Biotherapeutics Inc will post ($3.71) earnings per share for the current year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

TRADEMARK VIOLATION NOTICE: This news story was posted by Mideast Time and is owned by of Mideast Time. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.mideasttime.com/john-mcgrath-sells-14000-shares-of-atara-biotherapeutics-inc-atra-stock/1590120.html.

Several research firms recently commented on ATRA. Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Saturday, March 11th. Jefferies Group LLC set a $23.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, December 12th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 4th. Finally, Citigroup Inc set a $10.00 price target on Atara Biotherapeutics and gave the stock a “sell” rating in a research report on Thursday, March 16th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $24.00.

Several hedge funds and other institutional investors have recently modified their holdings of ATRA. Teachers Advisors LLC increased its position in shares of Atara Biotherapeutics by 27.4% in the third quarter. Teachers Advisors LLC now owns 130,251 shares of the company’s stock worth $2,786,000 after buying an additional 28,000 shares during the period. Eagle Asset Management Inc. increased its position in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock worth $20,976,000 after buying an additional 8,081 shares during the period. Neuberger Berman Group LLC increased its position in shares of Atara Biotherapeutics by 9.5% in the third quarter. Neuberger Berman Group LLC now owns 688,715 shares of the company’s stock worth $14,732,000 after buying an additional 59,595 shares during the period. Creative Planning purchased a new position in shares of Atara Biotherapeutics during the third quarter worth $213,000. Finally, Arrowpoint Asset Management LLC increased its position in shares of Atara Biotherapeutics by 18.2% in the fourth quarter. Arrowpoint Asset Management LLC now owns 1,560,612 shares of the company’s stock worth $22,161,000 after buying an additional 240,285 shares during the period. Institutional investors and hedge funds own 77.48% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.